SLC5A2 and diabetes mellitus: Despite their generally favorable safety profile and minimal adverse effects, SGLT2 is are also associated with ketoacidosis, with an incidence ranging from 1.4 to 8.8 events per 1,000 patient years among patients with diabetes who take these medications [7–12].